Source: http://www.google.com/patents/US8036833?dq=5,893,120
Timestamp: 2014-03-09 07:19:03
Document Index: 487926571

Matched Legal Cases: ['Application No. 2442604', 'Application No. 07810453', 'Application No. 2002', 'Application No. 2002', 'Application No. 2002', 'Application No. 2002', 'Application No. 2002311827', 'Application No. 02739157', 'Application No. 2002', 'Application No. 2002311827', 'Application No. 02', 'Application No. 2008', 'Application No. 2002', 'Application No. 2442604', 'Application No. 2008', 'Application No. 2002', 'Application No. 02739157', 'Application No. 02739157']

Patent US8036833 - Systems and methods for automated analysis of cells and tissues - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsSystems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed....http://www.google.com/patents/US8036833?utm_source=gb-gplus-sharePatent US8036833 - Systems and methods for automated analysis of cells and tissuesAdvanced Patent SearchPublication numberUS8036833 B2Publication typeGrantApplication numberUS 11/789,361Publication dateOct 11, 2011Filing dateApr 23, 2007Priority dateApr 20, 2001Also published asCA2442604A1, CA2442604C, EP1390747A1, EP1390747A4, US7219016, US7873480, US8121794, US8185320, US8639450, US20020177149, US20080013816, US20080026420, US20080046190, US20080056553, US20120329665, WO2002086498A1, WO2002086498A8Publication number11789361, 789361, US 8036833 B2, US 8036833B2, US-B2-8036833, US8036833 B2, US8036833B2InventorsDavid L. Rimm, Robert L. CampOriginal AssigneeYale UniversityExport CitationBiBTeX, EndNote, RefManPatent Citations (41), Non-Patent Citations (159), Referenced by (3), Classifications (18), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetSystems and methods for automated analysis of cells and tissuesUS 8036833 B2Abstract Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4998284Feb 24, 1989Mar 5, 1991Cell Analysis Systems, Inc.Dual color camera microscope and methodology for cell staining and analysisUS5386819Apr 14, 1993Feb 7, 1995Olympus Optical Co., Ltd.Method and apparatus for inhibiting a scattered component in a light having passed through an examined objectUS5784162Dec 12, 1995Jul 21, 1998Applied Spectral Imaging Ltd.Spectral bio-imaging methods for biological research, medical diagnostics and therapyUS5989835Feb 27, 1997Nov 23, 1999Cellomics, Inc.System for cell-based screeningUS5998151Nov 27, 1996Dec 7, 1999The United States Of America As Represented By The Department Of Health And Human ServicesMethods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthaseUS6026174Aug 8, 1997Feb 15, 2000Accumed International, Inc.System and method for automatically detecting malignant cells and cells having malignancy-associated changesUS6151405Mar 28, 1997Nov 21, 2000Chromavision Medical Systems, Inc.System and method for cellular specimen gradingUS6165734Nov 20, 1998Dec 26, 2000Applied Spectral Imaging Ltd.In-situ method of analyzing cellsUS6215892Nov 27, 1996Apr 10, 2001Chromavision Medical Systems, Inc.Method and apparatus for automated image analysis of biological specimensUS6229649Oct 4, 1994May 8, 2001The United States Of America As Represented By The Secretary Of The Air ForcePseudo deconvolution method of recovering a distorted optical imageUS6251601Feb 2, 1999Jun 26, 2001Vysis, Inc.Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarraysUS6337472Oct 19, 1998Jan 8, 2002The University Of Texas System Board Of RegentsLight imaging microscope having spatially resolved imagesUS6466690Dec 19, 2000Oct 15, 2002Bacus Research Laboratories, Inc.Method and apparatus for processing an image of a tissue sample microarrayUS6727071Feb 27, 1998Apr 27, 2004Cellomics, Inc.System for cell-based screeningUS7050087Dec 6, 2000May 23, 2006Bioview Ltd.Data acquisition and display system and methodUS7709222Jul 13, 2007May 4, 2010Yale UniversityMethods for making cancer prognoses based on subcellular localization of biomarkersUS7873480Aug 20, 2007Jan 18, 2011Yale UniversitySystems and methods for automated analysis of cells and tissuesUS20020094956Mar 12, 2002Jul 18, 2002Boys Town National Research HospitalUse of alpha1beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney diseaseUS20030036855Aug 16, 2002Feb 20, 2003Praelux Incorporated, A Corporation Of New JerseyMethod and apparatus for screening chemical compoundsUS20050227303Jun 6, 2005Oct 13, 2005Yajun GuoMethod and composition for diagnosis of melanocytic lesionsUS20060127928Sep 9, 2005Jun 15, 2006Bacus Sarah STargeted therapy marker panelsUS20060147959Dec 5, 2005Jul 6, 2006The General Hospital CorporationMethod to determine responsiveness of cancer to epidermal growth factor receptor targeting treatmentsUS20060275844Apr 18, 2006Dec 7, 2006Linke Steven PDiagnostic markers of breast cancer treatment and progression and methods of use thereofUS20080026420Jun 20, 2007Jan 31, 2008Yale UniversitySystems and methods for automated analysis of cells and tissuesUS20080046190Aug 20, 2007Feb 21, 2008Yale UniversitySystems and methods for automated analysis of cells and tissuesUS20080056553Aug 20, 2007Mar 6, 2008Yale UniversitySystems and methods for automated analysis of cells and tissuesUS20090155767Jun 27, 2008Jun 18, 2009Rimm David LMethods for a predictive diagnostic test for tamoxifenUS20090155842Nov 22, 2006Jun 18, 2009Johannes Pieter Albert BaakPrognostic assay for metachronous colorectal cancerWO1990010276A1Feb 23, 1990Aug 25, 1990Cell Analysis Systems IncDual color camera microscope and methodology for cell staining and analysisWO1997004418A1Jul 18, 1996Feb 6, 1997Morphometrix Techn IncMulti-spectral segmentation for image analysisWO1997022848A1Dec 10, 1996Jun 26, 1997Robert A BuckwaldMethod for simultaneous detection of multiple fluorophores for in situ hybridization and chromosome paintingWO1999047963A1Mar 16, 1999Sep 23, 1999Richard L HansenConfocal microscopy imaging systemWO2000024940A1Oct 28, 1999May 4, 2000Vysis IncCellular arrays and methods of detecting and using genetic disorder markersWO2000031534A1Nov 16, 1999Jun 2, 2000Applied Spectral Imaging LtdIn situ method of analyzing cellsWO2000062247A1Apr 10, 2000Oct 19, 2000Chromavision Med Sys IncHistological reconstruction and automated image analysisWO2001020044A2Sep 15, 2000Mar 22, 2001Lukas BudendorfSignal counting for in situ hybridizationWO2001022086A1Sep 22, 2000Mar 29, 2001Cohen JonathanA high-throughput system for evaluating the clinical utility of molecular targets in tissue samplesWO2002086498A1Apr 19, 2002Oct 31, 2002Univ YaleSystems and methods for automated analysis of cells and tissuesWO2008008500A2Jul 13, 2007Jan 17, 2008Univ YaleMethods for making cancer prognoses based on the subcellular localization of biomarkersWO2009005715A1Jun 27, 2008Jan 8, 2009Univ YaleMethods for a predictive diagnostic test for tamoxifenWO2009005816A1Jul 3, 2008Jan 8, 2009Gouldrothberg Bonnie EMethods for differential diagnosis of melanocytic lesionsNon-Patent CitationsReference1"Tamoxifen for early breast cancer: an overview of the randomised trials," Early Breast Cancer Trialists' Collaborative Group, Lancet, 351:1451-67, 1998.2Agard D A "Optical Sectioning Microscopy: Cellular Architecture in Three Dimensions," Annual Review of Biophysics and Bioengineering, Annual Reviews Inc., vol. 13, Jan. 1, 1984, pp. 191-219.3Apr. 14, 2011 Response to Dec. 21, 2010 Office Action issued in connection with U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.4Apr. 20, 2010 Response to the Office Action issued Oct. 20, 2009 by the Canadian Patent Office in connection with Canadian Patent Application No. 2442604 (national stage of PCT International Application No. PCT/US02/12084.5Apr. 26, 2011 Response to Oct. 14, 2010 Official Communication in Connection with European Patent No. 02739157.2 (National Stage of PCT International Application No. PCT/US02/12084).6Apr. 27, 2006 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.7Apr. 29, 2010 Response to Dec. 29, 2009 Office Action issued in connection with U.S. Appl. No. 12/215,458, filed Jun. 27, 2008.8Apr. 7, 2005 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.9Apr. 8, 2009 Response to the Official Communication Pursuant to Rules 161 and 162 issued by the European Patent Office in connection with European Patent Application No. 07810453.6 (national stage of PCT International Application No. PCT/US07/016014).10Arnold et al., "Molecular Determinants for Subcellular Localization of PSD-95 with an Interacting K+ Channel," Neuron, May 1999, 24:149-157.11Arpino G, Green SJ, Allred DC, et al. "HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study." Clin Cancer Res 10:5670-6, 2004.12Arpino G, Weiss H, Lee AV, et al. "Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance," J Natl Cancer Inst 97:1254-61, 2005.13Aschele C, Lonardi S, Monfardini S. "Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer," Cancer Treat Rev 2002;28(1):27-47.14Aug. 17, 2009 Response to Japanese Official Action issued issued Apr. 10, 2009 by the Japanese Patent Office in connection with Japanese Patent Application No. 2002-583976 (national stage of PCT International Application No. PCT/US02/12084).15Aug. 24, 2009 Response to Feb. 23, 2009 Office Action issued in connection with U.S. Appl. No, 11/827,694, filed Jul. 13, 2007.16Aug. 28, 2006 Response to Apr. 27, 2006 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.17Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, et al. "Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival," 25. Cancer Res. 2003;63(23):8103-8107.18Berger SH, Berger FG. "Thymidylate synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cell lines," Mol Pharmacol 1988;34(4):474-9.19Berger SH, Berger FG. "Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumor cell lines," Mol Pharmacol 1988;34(4):474-9.20Berger, A.J. at al. "Subcellular Localization of Activating Transcription Factor 2 in Melanoma Specimens Predicts Patient Survival," Cancer Research, Dec. 2003, vol. 63(23), pp. 8103-8107.21Bissoon-Haqqani S, Moyana T, Jonker D, Maroun JA, Birnboim HC. "Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples," J Histochem Cytochem 2006;54(1):19-29.22Brown et al., "A Two Focal Plane Method for Digital Quantification of Nuclear Immunoreactivity in Large Brain Areas Using NIH-image Software," Brain Research Protocols, 1998, vol. 2:264-272.23Bubendorf et al. "Survey of Gene Amplifications during Prostate Cancer Progression by High-Throughput Fluorescence in Situ Hybridication on Tissue Microarrays," Cancer Research (1999) vol. 59, pp. 803-806.24Camp RL, Charette LA, Rimm DL. "Validation of tissue microarray technology in breast carcinoma," 50. Lab Invest 2000;80(12):1943-1949.25Camp RL, Chung GG, Rimm DL. "Automated subcellular localization and quantification of protein expression in tissue microarrays," Nat.Med. 2002;8(11):1323-1327.26Camp RL, Chung GG, Rimm DL. "Automated subcellular localization and quantification of protein expression in tissue microarrays," Nat.Med. 2002;8(11):1323-1327.27Camp RL, Chung GG, Rimm DL. "Automated subcellular localization and quantification of protein expression in tissue microarrays," Nat Med 8:1323-7, 2002.28Camp RL, Dolled-Filhart M, King BL, et al. "Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome," Cancer Res 63:1445-8, 2003.29Camp RL, Dolled-Filhart M, Rimm DL. "X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization," 9. Clin.Cancer Res. 2004;10(21):7252-7259.30Cascinue S. et al., "Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to Leucovorin-modulated bolus 5-fluorouracil," Clinical Cancer Research, Aug. 1999, vol. 5, pp. 1996-1999.31Chen et al., "Ratio-Base Decisions and the Quantitative Analysis of cDNA Microarray Images," J. Biomed. Optics, Oct. 1997, 2(4):364-374.32Christensen TA, Reiter JL, Baron AT, et al. "Generation and characterization of polyclonal antibodies specific for human p110 sEGFR," Hybrid Hybridomics 21:183-9, 2002.33Ciardiello F, Tortora G. "Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs," Eur J Cancer 39:1348-54, 2003.34Dec. 18, 2003 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.35Dec. 21, 2010 Office Action in connection with U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.36Dec. 23, 2010 Office Action in connection with U.S. Appl. No. 11/894,297, filed Aug. 20, 2007.37Dec. 29, 2009 Office Action issued in connection with U.S. Appl. No. 12/215,458, filed Jun. 27, 2008.38Dolled-Filhart M, McCabe A, Giltnane J, et al. "Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome," Cancer Res 66:5487-94, 2006.39Dowsett M, Houghton J, Iden C, et al. "Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status," Ann Oncol 17:818-26, 2006.40Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, et al. "Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy," J Clin Oncol 2002;20(7):1721-8.41Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, et al. "Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival," Clin Cancer Res 2000;6(2):488-92.42Edler et al. "Immunohistochemically Detected Thymidylate Synthase in Colorectal Cancer: an Independent Prognostic Factor of Survival," Clinical Cancer Research, US vol. 6, No. 2, Feb. 1, 2000.43English translation of Official Action issued Apr. 10, 2009 by the Japanese Patent Office in connection with Japanese Patent Application No. 2002-583976 (national stage of PCT International Application No. PCT/US02/12084.44English translation of Official Action issued Jul. 4, 2007 by the Japanese Patent Office in connection with Japanese Patent Application No. 2002-583976 (national stage of PCT International Application No. PCT/US02/12084).45English translation of Official Action issued May 19, 2008 by the Japanese Patent Office in connection with Japanese Patent Application No. 2002-583976 (national stage of PCT International Application No. PCT/US02/12084.46European Search Report issued by the European Patent Office in connection with PCT/US2007016014 including Supplementary European Search Report and the European Search Opinion, Oct. 9, 2008.47Examiner's Report issued Nov. 15, 2006 by the Australian Patent Office in connection with Australian Patent Application No. 2002311827, now Australian Patent No. 2002311827 (national stage of PCT International Application No. PCT/US02/12084).48Feb. 11, 2010 Response to the Official Communication Pursuant to Article 94(3) from European Patent Office issued Oct. 1, 2009 in connection with European Patent Application No. 02739157.2 (national stage of PCT International Application No. PCT/US02/12084).49Feb. 19, 2010 Office Action issued in connection with U.S. Appl. No. 11/894,297, filed Aug. 20, 2007.50Feb. 23, 2009 Office Action in connection with U.S. Appl. No. 11/827,694, filed Jul. 13, 2007.51Feb. 3, 2010 Office Action issued in connection with U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.52Feb. 6, 2006 Response to Oct. 19, 2005 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.53Fernandez-Contreras et al. "Thymidylate synthase expression pattern is prognostic factor in patients of colorectal cancer treated with 5-fluorouracil," Int'l J. Oncol., Oct. 2004, vol. 25, No. 4, pp. 887-885, abstract only.54Forus et al., "Sensitive Fluorescent in situ Hybridisation Method for the Characterisation of Breast Cancer Cells in Bone Marrow Aspirates," The Journal of Clinical Pathology, 1999, 52:68-74.55Gee JM, Robertson JF, Gutteridge E, et al. "Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer," Endocr Relat Cancer 12 Suppl 1:S99-S111, 2005.56Giltnane JM, Rimm DL. "Technology insight: Identification of biomarkers with tissue microarray technology," Nat Clin Pract Oncol 2004;1(2):104-11.57Gustafsson et al. "I5M: 3D Widelight Light Microscopy with Better Than 100 nm Axial Resolution," Journal of Microscopy, 1999, vol. 195: 10-16.58Howell A, Cuzick J, Baum M, et al. "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer," Lancet 365:60-2, 2005.59International Preliminary Examination Report issued by the International Bureau in connection with International Application No. PCT/US2002/012084, Dec. 10, 2003.60International Preliminary Report on Patentability issued by the International Bureau in connection with International Application No. PCT/US2007/016014, Jan. 13, 2009.61International Preliminary Report on Patentability issued by the International Bureau in connection with International Application No. PCT/US2008/08007, Jan. 5, 2010.62International Preliminary Report on Patentability issued by the International Bureau in connection with International Application No. PCT/US2008/08229, Jan. 5, 2010.63International Search Report issued by the International Bureau in connection with International Application No PCT/US10/52471, Dec. 6, 2010.64International Search Report issued by the International Bureau in connection with International Application No. PCT/US 10/54799, Jan. 10, 2011.65International Search Report issued by the International Bureau in connection with International Application No. PCT/US2007/016014, Oct. 6, 2008.66International Search Report issued by the International Bureau in connection with International Application No. PCT/US2008/08007, Oct. 1, 2008.67International Search Report issued by the International Bureau in connection with International Application No. PCT/US2008/08229.68International Search Report issued by the International Searching Authority in connection with International Application No. PCT/US2002/012084, Sep. 19, 2002.69Jan. 24, 2007 Response to Nov. 24, 2006 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.70Jan. 4, 2008 Response to Japanese Official Action issued issued Jul. 4, 2007 by the Japanese Patent Office in connection with Japanese Patent Application No. 2002-583976 and English translation of the amended claims (national stage of PCT International Application No. PCT/US02/12084).71Johnston PG, Drake JC, Trepel J, Allegra CJ. "Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines," Cancer Res 1992;52(16):4306-12.72Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. "Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors," Cancer Res 1995;55(7):1407-12.73Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ. "Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue," Cancer Res 1991;51(24):6668-76.74Johnston SR. "Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer," Clin Cancer Res 12:1061s-1068s, 2006.75Jonat W, Pritchard KI, Sainsbury R, et al. "Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient," J Cancer Res Clin Oncol 132:275-86, 2006.76Jul. 15, 2008 Response to the Examiner's Report issued Nov. 15, 2006 by the Australian Patent Office in connection with Australian Patent Application No. 2002311827, now Australian Patent No. 2002311827 (national stage of PCT International Application No. PCT/US02/12084).77Jul. 22, 2010 Office Action issued in connection with U.S. Appl. No. 12/215,458, filed Jun. 27, 2008.78Jul. 25, 2011 Official Communication Pursuant to Article 94(3) EPC issued by the European Patent Office on Jul. 25, 2011 in Connection with European Application No. 02 739 157.2.79Jun. 1, 2010 Response to Mar. 1, 2010 Office Action issued in connection with U.S. Appl. No. 11/894,680, filed Aug. 20, 2007.80Jun. 16, 2004 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.81Jun. 22, 2010 Office Action issued in connection with U.S. Appl. No. 11/820,786, filed Apr. 23, 2007.82Jun. 22, 2010 Office Action issued in connection with U.S. Appl. No. 11/894,297, filed Aug. 20, 2007.83Jun. 23, 2011 Response to Office Action issued on Dec. 23, 2011 in connection with U.S. Appl. No. 11/894,297 filed Aug. 20, 2007.84Jun. 30, 2005 Response to Apr. 7, 2005 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.85Klein et al., "The Neuroimmune Interface in Prion Diseases," News Physiol. Sci., Oct. 2000, 15:250-255.86Konenen, et al. "Tissue Microarrays for High-Throughput Molecular Profiling of Tumor Specimens," Nature Medicine, Jul. 1998, vol. 4, No. 7, pp. 844-847.87Kucera R, Paulus H. "Localization of the deoxyribonucleotide biosynthetic enzymes ribonucleotide reductase and thymidylate synthase in mouse L cells," Exp Cell Res 1986;167(2):417-28.88Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al. "Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin," J Clin Oncol 1997;15(10):3223-9.89Leichman CG. "Thymidylate synthase as a predictor of response," Oncology (Williston Park) 1998;12(8 Suppl 6):43-7.90Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, et al. "Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial," Eur J Cancer 1995;31A(7-8):1306-10.91Linke SP, Bremer TM, Herold CD, et al. "A multimarker model to predict outcome in tamoxifen-treated breast cancer patients," Clin Cancer Res 12:1175-83, 2006.92Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell M, et al. "Thymidylate synthase as a translational regulator of cellular gene expression," Biochim Biophys Acta 2002;1587(2-3):174-82.93Mar. 1, 2010 Office Action issued in connection with U.S. Appl. No. 11/894,680, filed Aug. 20, 2007.94Mar. 2, 2004 Response to Dec. 18, 2003 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.95Mar. 26, 2010 Response to Feb. 19, 2010 Office Action issued in connection with U.S. Appl. No. 11/894,297, filed Aug. 20, 2007.96Mar. 3, 2010 Response to Feb. 3, 2010 Office Action issued in connection with U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.97Mar. 7, 2011 Written Argument and Amendment to Oct. 6, 2010 Official Action in connection with Japanese Patent Application No. 2008-00078 and English translation.98Matsumoto et al. "Markers of cell proliferation and expression of melanosomal antigen in lymphangioleimyomatosis," Am. J. Respir. Cell. Mol. Biol. Sep. 1999, vol. 21, No. 3 pp. 372-326.99McCabe A, Dolled-Filhart M, Camp RL, et al. "Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis," J Natl Cancer Inst 97:1808-15, 2005.100McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. "Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis," J Natl Cancer Inst 2005;97(24):1808-15.101McCabe et al. "Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis," Journal of the National Cancer Institute, vol. 97. No. 24, Dec. 2, 2005.102Nicholson RI, McClelland RA, Finlay P, et al. "Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity," Eur J Cancer 29A:1018-23, 1993.103Nicholson RI, McClelland RA, Gee JM, et al. "Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy," Breast Cancer Res Treat 29:117-25, 1994.104Notice of Allowance issued Aug. 20, 2010 in connection with U.S. Appl. No. 11/894,680, filed Aug. 20, 2007.105Nov. 24, 2006 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.106Oct. 19, 2005 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.107Oct. 20, 2010 Response to Jul. 22, 2010 Office Action in connection with U.S. Appl. No. 12/215,458, filed Jun. 27, 2008.108Oct. 7, 2008 Response to Japanese Official Action issued issued May 19, 2008 by the Japanese Patent Office in connection with Japanese Patent Application No. 2002-583976 and Englisht translation of the amended claims (national stage of PCT International Application No. PCT/US02/12084).109Office Action issued Oct. 20, 2009 by the Canadian Patent Office in connection with Canadian Patent Application No. 2442604 (national stage of PCT International Application No. PCT/US02/12084.110Office Action issued on Jun. 16, 2011 in connection with U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.111Official Action issued Oct. 6, 2010, by the Japanese Patent Office in connection with Japanese Patent Application No. 2008-78 and English translation of same(divisional application of Japanese Patent Application No. 2002-583976, national stage of PCT International Application No. PCT/US02/12084.112Official Communication Pursuant to Article 94 (3) from European Patent Office dated Oct. 14, 2010 in connection with European Patent Application No. 02739157.2 (regional stage of PCT International Application No. PCT/US02/12084).113Official Communication Pursuant to Article 94(3) from European Patent Office dated Oct. 1, 2009 in connection with European Patent Application No. 02739157.2 (national stage of PCT International Application No. PCT/US02/12084).114Osborne CK, Shou J, Massarweh S, et al. "Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer," Clin Cancer Res 11:865s-70s, 2005.115Osborne CK. "Tamoxifen in the treatment of breast cancer," N Engl J Med 339:1609-18, 1998.116PCT International Application No. PCT/US/2010/052471, filed Oct. 13, 2010 (Yale University et al.).117PCT International Application No. PCT/US2010/054799, filed Oct. 29, 2010 (Yale University et al.).118Pending claims for U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.119Pending claims for U.S. Appl. No. 11/894,297, filed Aug. 20, 2007.120Pending claims for U.S. Appl. No. 11/894,680, filed Aug. 20, 2007.121Pending claims for U.S. Appl. No. 12/215,458, filed Jun. 27, 2008.122Popat S, Matakidou A, Houlston RS. "Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis," J Clin Oncol 2004;22(3):529-36.123Psyrri Amanda et al. "Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis," Clinical Cancer Research, vol. 11(16), Aug. 15, 2005.124Punglia RS, Kuntz KM, Winer EP, et al. "The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis," Cancer 106:2576-82, 2006.125Raeside DE. "Monte Carlo principles and applications," Phys Med Biol 1976;21(2):181-97.126Reiter JL, Maihle NJ. "Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta," Ann N Y Acad Sci 995:39-47, 2003.127Rigaut et al., "Three-Dimensional DNA Image Cytometry by Confocal Scanning Laser Microscopy in Thick Tissue Blocks," Cytometry, 1991, 12:511-524.128Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. "Tissue microarray: a new technology for amplification of tissue resources," Cancer J. 2001;7(1):24-31.129Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. "Amplification of tissue by construction of tissue microarrays," Exp Mol Pathol 2001;70(3):255-64.130Rothberg, B.E.G et al, "Melanoma Progostic Model Using Tissue Microarray and Genetic Algorithms," Journal of Oncology Nov. 2, 2009, vol. 27(34), pp. 5572-5780: abstract.131Rothberg, B.G., et al. "Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms," J Clin Oncol 2009; 27:5772-5780.132Rubin MA, Zerkowski MP, Camp RL, et al. "Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements," Am J Pathol 164:831-40, 2004.133Ryden L, Jirstrom K, Bendahl P-O, et al. "Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer," J Clin Oncol 23:4695-4704, 2005.134Ryden L, Jonsson PE, Chebil G, et al. "Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up," Eur J Cancer 41:256-64, 2005.135Santi DV. "The mechanism and structure of thymidylate synthetase," Nucleic Acids Symp Ser 1986(17):125-6.136Santini D. et al. "Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy," Oncology, 2004, vol. 67, pp. 135-142.137Scagliotti, et al. "Phase III Study Comparing Cisplatin Plus Gemcitabine with Cisplatin Plus Pemetrexed in Chemotherapy-Na�ve Patients with Advanced-Stage Non-Small-Cell Lung Cancer," J Clin Oncol. Epub May 27, 2008, 26(1): 3543-51.138Schiff R, Massarweh SA, Shou J, et al. "Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators," Cancer Chemother Pharmacol 56 Suppl 1:10-20, 2005.139Schlessinger J. "Cell signaling by receptor tyrosine kinases," Cell 103:211-25, 2000.140Schlessinger J. "Cell signaling by receptor tyrosine kinases," Cell 103:211-25, 2000.141Sep. 16, 2004 Response to Jun. 14, 2004 Office Action issued in connection with U.S. Appl. No. 10/062,308, filed Feb. 1, 2002, now U.S. Patent No. 7,219,016.142Sep. 22, 2010 Response to Jun. 22, 2010 Office Action issued in connection with U.S. Appl. No. 11/820,786, filed Jun. 20, 2007.143Sep. 22, 2010 Response to Jun. 22, 2010 Office Action issued in connection with U.S. Appl. No. 11/894,297, filed Aug. 20, 2007.144Shah, et al., "Expression of Syndecan-1 and Expression of Epidermal Growth Factor Receptor are Associated with Survival in Patients with Nonsmall Cell Lung Carcinoma," Cancer 2004, 101(7): 1632-1638.145Slingluff, C.L. et al. "Lethal "Thin" Malignant Melanoma Identifying Patients at Risk," Ann. Surg. Aug. 1998, vol. 208(2), pp. 150-161.146Staines et al., "Three-Color Immunofluorescence Histochemistry Allowing Triple Labeling Within a Single Section," The Journal of Histochemistry and Cytochemistry, (1988), 36(6):145-151.147Sundram et al. "Expression of the B-Cell Proliferation Marker MUM1 by Melanocytic Lesions and Comparison with S100, gp100 (HMB45), and MelanA," Mod. Pathol. 3003, vol. 16, No. 8 pp. 802-810.148Supplemental European Search report issued by European Patent Office in connection with International Application No. PCT/US2002/012084, Sep. 19, 2002.149U.S. Appl. No. 12/661,141, filed Mar. 10, 2010 to David L. Rimm et al.150Vollmer et al. "Use of Bayes Rule and MIB-1 Proliferation Index to Discriminate Spitz Nevus From Malignant Melanoma," Am. J. Clin. Pathol. 2004, vol. 122, pp. 499-505.151Wang, et al. "Identification of Genes Differentlly Over-Expressed in Lung Squamous Cell Carcinoma using Combination of cDNA Subtraction and Microarray Analysis," Oncogene 2000, 19:1519-1528.152Wong NA, Brett L, Stewart M, Leitch A, Longley DB, Dunlop MG, et al. "Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma," Br J Cancer 2001;85(12):1937-43.153Wood et al., "B-Spectrin is Colocalized with Both Voltage-gated Sodium Channels and AnkyrinG at the Adult Rat Neuromuscular Junction," The Journal of Cell Biology, 1998, 140(3):675-684.154Written Opinion of the International Searching Authority issued by the International Search Authority (ISA/US) in connection with International Application No. PCT/US10/52471 including Supplementary European Search Report and the European Search Opinion, Jan. 10, 2011.155Written Opinion of the International Searching Authority issued by the International Search Authority (ISA/US) in connection with International Application No. PCT/US10/54799, Jan. 10, 2011.156Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2007/016014, Oct. 6, 2008.157Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2008/08007, Oct. 1, 2008.158Written Opinion of the International Searching Authority issued the International Searching Authority (ISA/US) in connection with International Application No. PCT/US2008/08229.159Zhon et al., "A Multiple Wavelength Algorithm in Color Image Analysis and Its Applications in Stain Decomposition in Microscopy Images," Med. Phys., 1996, 23(12):1977-1986.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8367351May 7, 2007Feb 5, 2013Historx, Inc.Methods for determining signal transduction activity in tumorsUS8497080Feb 5, 2013Jul 30, 2013Historx, Inc.Methods for determining signal transduction activity in tumorsUS8639450May 2, 2012Jan 28, 2014Yale UniversitySystems and methods for automated analysis of cells and tissuesClassifications U.S. Classification702/19International ClassificationG01N21/64, G01N33/48, G06T7/00, G01N21/27Cooperative ClassificationG06T7/401, G06T2207/30072, G06T2207/20101, G06T7/0012, G02B21/16, G06T2207/30024, G01N21/6458, G06T2207/20036, G02B21/367European ClassificationG01N21/64P4C, G02B21/36V1, G06T7/00B2, G06T7/40ALegal EventsDateCodeEventDescriptionApr 14, 2008ASAssignmentOwner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OFFree format text: CONFIRMATORY LICENSE;ASSIGNOR:YALE UNIVERSITY;REEL/FRAME:020800/0199Effective date: 20080414RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google